Champions Oncology, Inc. (CSBR) — Analysis Summary
Champions Oncology, Inc. (CSBR) has a market cap of $78.60M with year-over-year revenue growth of +13.5%. Net margin stands at 8.3%. The stock trades at a P/E ratio of -33.5.
Key Takeaways
- Revenue changed +13.5% year-over-year
- Net margin of 8.3%
- P/E ratio of -33.5
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, CSBR posted revenue growth of +13.5% and trades at a P/E of -33.5.
Champions Oncology, Inc. (CSBR)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Net income turned negative after a profitable prior period.
Current ratio at 0.98x — current liabilities exceed current assets
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees
306
Headquarters
BALTIMORE, MD
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.